bispecific antibodies

mountain climb steep cliff climber struggle

Previewing Akeso's high-stakes ASCO plenary for PD-1/VEGF

If successful, ivonescimab would be the first regimen to show a survival benefit over a PD-1/chemotherapy combo in first-line NSCLC in a phase 3 trial.

Angus Liu May 27, 2026 11:25am

ASCO: Merck, Kelun's sac-TMT combo beats Keytruda by 65% on PFS

May 21, 2026 5:00pm

Partner's Bizengri passes muster in FDA national priority pilot

May 11, 2026 11:08am

Prolific's light-controlled manufacturing system sets mAb record

May 5, 2026 10:00am

Summit shares tumble on interim PD-1/VEGF trial miss

May 1, 2026 10:56am

Pfizer looks to jump start Elrexfio with topline win

Apr 29, 2026 10:16am